WHO Approves First Malaria Drug for Newborns

WHO Approves First Malaria Drug for Newborns

Why in News?

Recently, the World Health Organization (WHO) approved the first newborn-specific malaria drug (artemether-lumefantrine), addressing a major treatment gap by ensuring safe, accurate dosing for infants.

Highlights of WHO Approved First Malaria Drug for Newborns

• Approval: The World Health Organization prequalified the first-ever malaria drug specifically for newborns and infants on 24 April 2026, marking a major breakthrough in pediatric malaria care and global health policy. 
• Official Name: The drug is called Coartem Baby. It is the first pharmaceutical formulation specifically labeled for the neonatal population. 
• Development: The drug was developed by Novartis in partnership with Medicines for Malaria Venture (MMV), highlighting public-private collaboration in global health.
• Target Age: It is specifically designed for newborns and infants weighing 2–5 kg, a group previously excluded from standard malaria treatments due to safety concerns. 

• Active Ingredients: It uses artemether-lumefantrine as its core. 
  • These two chemicals work together to kill malaria parasites fast. 
  • This combination is the gold standard for treating P. falciparum malaria.
• Tablet Design: The drug comes as a dispersible tablet. 
  • It dissolves rapidly in small amounts of liquid like water. 
• Palatable Flavor: The tablets have a sweet cherry taste. This flavor masks the natural bitter profile of the medicine.
• Scientific Basis: The efficacy and safety of this drug were tested through the CALINA Study (Phase II/III Clinical Trial), in which 8 countries in Africa participated.
• Efficacy: The malaria clearance rate (PCR-corrected ACPR) by day 29 was 95.5% in cohort 1 (>28 days) and 100% in cohort 2 (≤28 days).
  • The children were found to be normal in the neurodevelopmental assessment done after 12 months. 

Need for Newborn-Specific Malaria Treatment

• High Mortality: Children under five account for 75% of global malaria deaths, totaling approximately 610,000 annual fatalities. Newborns represent the most vulnerable subset of this group, yet they previously lacked specialized pharmaceutical tools to combat the infection.
• Treatment Gap: Before 2026, there were no antimalarials approved for infants weighing 2 kg to 5 kg. Approximately 30 million babies are born annually in malaria-endemic regions; this drug finally provides a safe, clinically proven option for this specific weight class.
• Dosing Safety: Physicians previously used “off-label” adult tablets by crushing them into imprecise fragments. This created a severe risk of dosage mistakes and toxicity because a newborn’s immature liver cannot metabolize drugs the same way as adults or older children. 
• Poor Compliance: Standard antimalarials are notoriously bitter, causing infants to vomit and fail treatment. Coartem Baby features a dispersible tablet design that dissolves in breast milk, ensuring the baby swallows the complete life-saving dose.
• Diagnosis Mimicry: Neonatal malaria often presents with fever and refusal to feed, symptoms that mimic neonatal sepsis. By providing a validated treatment, health systems can better manage cases where malaria is a confirmed, yet previously untreatable, cause of illness.
• Donor Procurement: WHO prequalification allows international agencies like UNICEF to bulk-buy the drug for countries with weak regulatory systems. This status fast-tracks distribution to Sub-Saharan Africa, where 95% of all cases and deaths occur.

WHO’s Role in Global Malaria Control and Policy Implications

• Technical Leadership: The WHO Global Malaria Programme (GMP) coordinates international efforts to control and eliminate malaria. 
  • Its primary goal is to guide the global response through the Global Technical Strategy (GTS) for Malaria 2016–2030, which was updated in 2021.
• Normative Standards: WHO develops evidence-based guidelines and terminology to ensure consistent global policy. 
  • These “living guidelines” are regularly updated, including the WHO terminologies 2025, providing a common technical language for scientific and programmatic use. 
• Policy Advice: The Malaria Policy Advisory Group (MPAG), comprising 16 independent experts, provides strategic advice twice annually. 
  • It assesses technical data to recommend appropriate malaria policies and identify major challenges to achieving global health goals.
• Surveillance Framework: The Organization maintains the Malaria Surveillance Assessment Toolkit to help countries track disease trends. 
  • Strong surveillance enables national programs to shift from reactive to predictive responses, identifying outbreaks before they escalate. 
• Vaccine Policy: Since 2021, WHO has recommended the broad use of RTS,S and R21/Matrix-M vaccines. 
  • As of early 2026, these are being rolled out in 25 countries, with the policy emphasizing their use alongside existing tools like bed nets. 
• Resistance Management: WHO monitors biological threats, specifically artemisinin partial resistance now confirmed in four African countries. 
  • The 2022 strategy to curb drug resistance in Africa promotes innovative approaches like multiple first-line therapies (MFT). 
• Impact Monitoring: The annual World Malaria Report serves as a vital diagnostic tool, tracking cases and deaths across 80 endemic countries. 
  • In 2024, an estimated 282 million cases were reported, highlighting a critical need for intensified global action.
• Elimination Certification: WHO officially certifies countries as malaria-free after three consecutive years of zero indigenous cases.
  • To date, 47 countries have been certified, including recent milestones like Egypt in 2024 and Timor-Leste in 2025.